Ivo T. Sklenar

Suggest Changes
Learn More
PURPOSE To determine whether recombinant human interleukin-3 (rhIL-3) reduces bone marrow depression and improves chemotherapeutic schedule adherence in ovarian cancer patients receiving first-line(More)